Healthcare Industry News: amlodipine
News Release - May 1, 2006
FDA Approves Higher Dose Formulations of Diovan HCT(R) (valsartan/hydrochlorothiazide) for Treatment of High Blood PressureProvides Physicians with Efficacious Treatment Option
High Blood Pressure Currently Uncontrolled in Half of Patients Taking Medications for the Condition
EAST HANOVER, N.J., May 1 (HSMN NewsFeed) -- The U.S. Food and Drug Administration (FDA) approved two new, higher dose formulations of the high blood pressure medication Diovan HCT® (valsartan/hydrochlorothiazide): 320/12.5 mg and 320/25 mg. The approval of the higher strengths of Diovan HCT provides more options to help physicians more effectively manage their patients' high blood pressure. The new formulations of Diovan HCT will be commercially available by early June 2006.
Diovan HCT is a combination of the efficacious blood pressure medicine Diovan® (valsartan), the most prescribed agent in the ARB (angiotensin receptor blocker) class, and the diuretic hydrochlorothiazide (HCTZ). The majority of high blood pressure patients will require a combination of two therapies, like Diovan HCT, to achieve blood pressure goals. Diovan HCT provides greater blood pressure-lowering benefits to patients who require more than either the diuretic or Diovan alone. Previously, Diovan HCT was available in 80/12.5 mg, 160/12.5 mg, and 160/25 mg tablets.
"Millions of patients already rely on Diovan and Diovan HCT to help them get to goal and maintain healthier blood pressure levels," said Alex Gorsky, head of pharma, North America and chief executive officer, Novartis Pharmaceuticals Corporation. "The approval and availability of these new formulations means that, with Diovan HCT, physicians will have the widest and most flexible range of dosing options in the ARB class."
High blood pressure is a public health crisis, affecting more than 65 million Americans or one in three adults. The risk of cardiovascular disease doubles with every increase of 20/10 mmHg above a healthy blood pressure of 115/75 mmHg. High blood pressure medications not only lower blood pressure, but also reduce the risk of suffering a stroke or heart attack. Overall 70 percent of people with high blood pressure do not have their condition controlled. Moreover, about half of those taking medication for their condition do not have it successfully managed, underscoring the need for more powerful treatments.
Details of Data Supporting Approval
Data supporting approval showed the new higher doses of Diovan HCT provided significantly greater reductions in blood pressure compared to either therapy alone. Diovan HCT 320/25 mg lowered systolic/diastolic blood pressure 25/17 mmHg compared to 6/7 mmHg with placebo alone.
The blood-pressure lowering effect of the high doses of Diovan HCT was maintained throughout long-term follow-up studies lasting up to one year (without placebo control), and was the same regardless of age or gender, and for black and non-black patients.
The overall incidence of adverse events with Diovan HCT was comparable to placebo. Further, giving Diovan in combination with HCTZ lowered the incidence of hypokalemia (low blood potassium) associated with HCTZ. Hypokalemia can cause cardiac arrhythmia, muscle pain and/or weakness, general discomfort, irritability, extreme thirst, frequent urination and confusion.
Data To Be Presented At ASH
Much of the data supporting approval of the higher dose formulations of Diovan HCT will be presented at the upcoming American Society of Hypertension, Inc. (ASH) Annual Scientific Meeting and Exposition May 16-20, 2006, in New York, NY. In total, more than 30 studies related to Diovan, Diovan HCT and other Novartis medications for treating high blood pressure will be presented. The presentations will include clinical data on the efficacy of Rasilez® (aliskiren) and Exforge® (amlodipine besylate/valsartan), both investigational agents for which Novartis recently submitted new drug applications to the FDA for their use in treating high blood pressure.
"The breadth and depth of data to be presented at ASH underscore Novartis' innovation and leadership in the hypertension category," Mr. Gorsky added. "We continue to strongly support a robust research program to fully develop Diovan and Diovan HCT, as well as investigate new therapies such as Rasilez and Exforge."
About Diovan and Diovan HCT
Diovan and Diovan HCT should be discontinued as soon as pregnancy is detected because it may cause harm or even death to the unborn child. If you get pregnant or plan to get pregnant, call your doctor right away.
Do not take Diovan or Diovan HCT if you are allergic to any of the ingredients in these products.
Do not take Diovan HCT if you have a history of reduced urine output, or have allergic reactions to certain drugs known as sulfonamides. If you're taking Diovan HCT, tell your doctor about all your medical conditions and medicines you take, including: liver or kidney problems, lupus or if you take lithium.
In clinical studies with Diovan and Diovan HCT, side effects have generally been mild. The most serious side effects with both Diovan and Diovan HCT are low blood pressure (hypotension) and kidney problems, and additionally with Diovan HCT, skin rash. The only side effect that was more frequent with Diovan HCT than placebo was nasopharyngitis (2.4% vs 1%). In individual studies, a dose-related increase in the incidence of dizziness was observed Diovan HCT-treated patients.
Diovan HCT is not for the initial treatment of high blood pressure. Diovan HCT may be the right medication for you if Diovan or certain other blood pressure medicines alone have not worked.
For more information or full prescribing information for Diovan or Diovan HCT, go to "Prescribing Info/Quick Download" at http://www.pharma.us.novartis.com or call Maura Bergen at 862-778-4146 or Christine Cascio at 862-778-8026.
The foregoing release contains forward-looking statements that can be identified by terminology such as "studies showed," "appeared to," "strongly support," or by discussions regarding potential new indications or labelling for Diovan and/or Diovan HCT, or regarding the long-term impact of a patient's use of Diovan and/or Diovan HCT. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results with Diovan and/or Diovan HCT to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Diovan and/or Diovan HCT will be approved for any additional indications or labelling in any market. In particular, management's expectations regarding Diovan and/or Diovan HCT could be affected by, among other things, additional analysis of Diovan and/or Diovan HCT clinical data; new clinical data; unexpected clinical trial results; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; increased government pricing pressures, and other risks and factors referred to in the Company's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets leading innovative prescription drugs used to treat a number of diseases and conditions, including central nervous system disorders, organ transplantation, cardiovascular diseases, dermatological diseases, respiratory disorders, cancer and arthritis. The company's mission is to improve people's lives by pioneering novel healthcare solutions.
Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG (NYSE: NVS ), a world leader in offering medicines to protect health, treat disease and improve well-being. Our goal is to discover, develop and successfully market innovative products to treat patients, ease suffering and enhance the quality of life. Novartis is the only company with leadership positions in both patented and generic pharmaceuticals. We are strengthening our medicine-based portfolio, which is focused on strategic growth platforms in innovation-driven pharmaceuticals, high-quality and low-cost generics and leading self-medication OTC brands. In 2005, the Group's businesses achieved net sales of USD 32.2 billion and net income of USD 6.1 billion. Approximately USD 4.8 billion was invested in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 91,000 people and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com .
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.